BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6689385)

  • 1. Oral and pharyngeal cancer: combined approach for multimodal therapy.
    Fazio M; Badellino F; Sannazzari GL; Vercellino V; Airoldi M; Manca A; Gandolfo S
    Tumori; 1983 Dec; 69(6):563-6. PubMed ID: 6689385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined cryosurgical, chemotherapeutic, and radiotherapeutic management of T1-4N0M0 oral cavity cancers.
    Airoldi M; Fazio M; Gandolfo S; Vercellino V; Ozzello F; Pedani F; Camoletto D; Negri L
    Cancer; 1985 Aug; 56(3):424-31. PubMed ID: 3839159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent progress in the treatment of oral and pharyngeal cancer].
    Uchida M; Nigauri T; Shimada S; Inoue A
    Gan To Kagaku Ryoho; 1991 Sep; 18(12):2070-6. PubMed ID: 1888178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.
    Park Y; Okamura K; Mitsuyama S; Saito T; Koh J; Kyono S; Higaki K; Ogita M; Asaga T; Inaji H; Komichi H; Kohno N; Yamazaki K; Tanaka F; Ito T; Nishikawa H; Osaki A; Koyama H; Suzuki T
    Br J Cancer; 2009 Aug; 101(4):598-604. PubMed ID: 19638976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
    Howell A; Rubens RD; Bush H; George WD; Howat JM; Crowther D; Sellwood RA; Hayward JL; Knight RK; Bulbrook RD
    Recent Results Cancer Res; 1984; 96():74-89. PubMed ID: 6396780
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.
    Nishikawa D; Hanai N; Ozawa T; Hirakawa H; Suzuki H; Nakashima T; Hasegawa Y
    Auris Nasus Larynx; 2015 Apr; 42(2):150-5. PubMed ID: 25498333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy of breast cancer: a Southwest Oncology Group experience.
    Rivkin SE; Glucksberg H; Foulkes M
    Recent Results Cancer Res; 1984; 96():166-74. PubMed ID: 6396770
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chemotherapy and partial surgery in epithelioma of the pharyngo-larynx].
    Laccourreye H; Bonfils P; Brasnu D; Ménard M; Fabre A; Janot F; Bassot V
    Ann Otolaryngol Chir Cervicofac; 1988; 105(6):409-14. PubMed ID: 2462398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
    Calais G; Berger C; Descamps P; Chapet S; Reynaud-Bougnoux A; Body G; Bougnoux P; Lansac J; Le Floch O
    Cancer; 1994 Aug; 74(4):1283-8. PubMed ID: 8055449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
    J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous radiochemotherapy for recurrent and metastatic breast carcinoma: evaluation of two treatment concepts.
    Plasswilm L; Seegenschmiedt MH; Ganssauge F; Sauer R
    Am J Clin Oncol; 1996 Aug; 19(4):403-7. PubMed ID: 8677915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer.
    Depondt J; Gehanno P; Martin M; Lelievre G; Guerrier B; Peytral C; Schott H; Pellae-Cosset B
    Oncology; 1993 Nov; 50 Suppl 2():23-7. PubMed ID: 8233298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy in early-stage and locally advanced small bulk squamous cell carcinoma of the oral cavity and oropharynx.
    Tichler T; Ramon Y; Rath P; Hendler S; Brenner HJ
    Isr J Med Sci; 1988; 24(9-10):539-44. PubMed ID: 2462551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.